# NCT02273375 (NCT02273375)

> Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02273375
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Canadian Cancer Trials Group
- Conditions: Non-Small Cell Lung Cancer
- Interventions: MEDI4736; Placebo
- Enrollment: 1415
- Primary outcome: Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 Deletions or ALK Gene Rearrangements

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02273375